autologous stem cells + platelet-rich plasma (Lung Institute)

This therapy involves the isolation and re-administration of a patient's own (autologous) stem cells, typically derived from bone marrow or adipose tissue, in combination with platelet-rich plasma (PRP). Developed by the Lung Institute, the treatment was marketed for chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). The proposed mechanism involves the anti-inflammatory and regenerative properties of mesenchymal stem cells and growth factors within the PRP to repair damaged lung tissue and improve pulmonary function. The therapy was evaluated in a Phase 1 clinical trial (NCT02216630) to assess safety and efficacy. However, the Lung Institute's practices have been subject to significant scrutiny and legal challenges due to a lack of robust clinical evidence and regulatory oversight, and the clinic has since undergone major operational changes.

Other names

Autologous Stem Cell Treatment for Chronic Lung DiseaseLung Institute Stem Cell TherapyAutologous Stem Cell and Platelet-Rich Plasma Therapy